HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation

Serrano, David; Carrión, Rafael; Balsalobre, Pascual; Miralles, Pilar; Berenguer, Juan; Buño, Ismael; Gomez-Pineda, Alfonso; Ribera, Josep‐Marǐa; Conde, Eulogio; Díez-Martín, José Luís

doi:10.1016/j.exphem.2004.12.008

Cited by 77 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there may be no role for rituximab in CD20-negative PBL, it may have potential in those PBL cases with weak CD20 expression. Autologous stem cell transplantation (SCT) in the management of HIV-associated lymphomas has shown to be feasible and effective [45,46], but its role in HIV-associated PBL is unclear. In fact, DLBCL with plasmablastic differentiation have shown to be resistant to standard chemotherapy and even SCT [43].…”

Section: Discussionmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a distinct subtype of non-Hodgkin B-cell lymphoma, originally described with a strong predilection to the oral cavity of human immunodeficiency virus (HIV)-infected individuals. Data regarding patient age and gender, HIV status, initiation of and response to highly active antiretroviral therapy (HAART), tumor extent, pathology, treatment, and outcome were extracted from 112 cases of PBL identified in the literature. The median age at presentation was 38 years with a male predominance of 7:1, and the median CD41 count was 178 cells/mm 3 . PBL presented on average 5 years after diagnosis of HIV. Common primary sites of presentation included the oral cavity, gastrointestinal tract, and lymph nodes. Most cases presented with either stage I or stage IV disease. There was a variable expression of B-cell markers in tumor cells, but plasma cell markers were expressed in all cases. EBV was detected in 74%. Chemotherapy was used to treat 55% patients and was combined with radiotherapy in 21% cases. Complete response was obtained in 66% of treated cases; the majority of these responses were seen after CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). The refractory/relapsed disease rate was 54%. Death occurred in 53% of patients, with a median overall survival of 15 months. Sex, CD41 count, viral load, clinical stage, EBV status, primary site of involvement, and use of CHOP failed to show an association with survival. PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men. Am. J. Hematol. 83:804-809, 2008. V

show abstract

Section: Discussionmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

show abstract

“…17,18,23 Moreover, they suggested an encouraging clinical efficacy of this procedure in patients with relapsed or refractory lymphoma or in high-risk CR, at least in small series of patients. 19,20,22 These studies enrolled patients after response to salvage therapy, at the time of stem cell collection, and selection of patients might have been substantial. French investigators, in a recent retrospective analysis, 21 reported less enthusiastic results in a heterogeneous group of patients, including subjects with chemorefractory disease.…”

Section: Discussionmentioning

confidence: 99%

“…High-dose therapy (HDT) with peripheral blood stem cell (PBSC) transplantation (PBSCT), which is the treatment of choice for relapsing or refractory HL or NHL in HIV-negative patients, 15,16 has been recently explored by several centers in the HIV setting, showing the feasibility of the procedure in terms of stem cell mobilization, engraftment, and low regimen-related toxicity 17,18 and showing antilymphoma efficacy. [19][20][21][22] However, selection of patients in these studies is not known and might have been substantial. Within the Italian Cooperative Group on AIDS and Tumors (GICAT) we started in 2000 a prospective multicentric study with the use of HDT and PBSCs as salvage therapy in HIV-positive patients with refractory or relapsed HL or NHL.…”

Section: Introductionmentioning

confidence: 99%

High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors

Michieli

Casari

et al. 2009

Blood

125

View full text Add to dashboard Cite

“…Nevertheless, a significant difference in ASCT outcome has been reported in the literature, mainly as a result of a selection of the patients included in the studies [1][2][3][4][5][6]. Focusing in particular on two of these trials, among the 14 patients included in the study by Gabarre and colleagues [4], only 4 patients were in complete remission at 49 months and one presented lymphoma relapse at 36 months after ASCT.…”

mentioning

confidence: 99%

“…Autologous stem cell transplantation (ASCT) has acquired a well-established role in the setting of HIV-positive patients affected by relapsed or partially responding lymphoma (RPRL) [1][2][3][4][5][6]. In this population, ASCT has proved to be an effective, feasible, and safe procedure ensuring comparable survival outcomes in both HIV-positive and negative individuals [7].…”

mentioning

confidence: 99%